- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/605 - Glucagons
Patent holdings for IPC class C07K 14/605
Total number of patents in this class: 1759
10-year publication summary
|
113
|
91
|
134
|
138
|
137
|
166
|
141
|
176
|
178
|
76
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novo Nordisk A/S | 2303 |
114 |
| Eli Lilly and Company | 4048 |
87 |
| Hanmi Pharm. Co., Ltd. | 597 |
85 |
| Zealand Pharma A/S | 268 |
79 |
| Sanofi | 4249 |
46 |
| Indiana University Research and Technology Corporation | 785 |
22 |
| Sun Pharmaceutical Industries Limited | 719 |
22 |
| MedImmune Limited | 611 |
20 |
| Takeda Pharmaceutical Company Limited | 2716 |
18 |
| Boehringer Ingelheim International GmbH | 4496 |
17 |
| Hanmi Science Co., Ltd. | 132 |
16 |
| Merck Sharp & Dohme LLC | 3732 |
16 |
| The Trustees of the University of Pennsylvania | 4406 |
15 |
| The Scripps Research Institute | 1340 |
15 |
| I2o Therapeutics, Inc. | 30 |
15 |
| President and Fellows of Harvard College | 6055 |
14 |
| Hybio Pharmaceutical Co., Ltd. | 121 |
14 |
| Ip2ipo Innovations Limited | 169 |
14 |
| Duke University | 3170 |
12 |
| Bachem Holding AG | 43 |
12 |
| Other owners | 1106 |